Nuwellis(NUWE.US)

Company Encyclopedia
View More
name
Nuwellis
NUWE.US
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Indonesia, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom.
1.378 T
NUWE.USMarket value -Rank by Market Cap -/-

Financial Score

01/01/2026 Update
C
Health Care EquipmentIndustry
Industry Ranking105/175
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-467.58%E
    • Profit Margin-202.83%E
    • Gross Margin65.18%A
  • Growth ScoreC
    • Revenue YoY-8.93%D
    • Net Profit YoY3.04%C
    • Total Assets YoY18.67%A
    • Net Assets YoY23.12%A
  • Cash ScoreD
    • Cash Flow Margin-49.31%D
    • OCF YoY-8.93%D
  • Operating ScoreA
    • Turnover1.11A
  • Debt ScoreC
    • Gearing Ratio50.98%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Lenox Hill Hospital Study Highlights the Broad Utility of Aquadex in Managing Fluid Overload Across Critical Care Settings | NUWE Stock News

    Nuwellis, Inc. presented a study at ASN Kidney Week 2025, showcasing Aquadex's effectiveness in fluid management for patients with acute kidney injury and complex conditions. The study, conducted at Lenox Hill Hospital, reviewed 69 cases and demonstrated predictable fluid removal, supporting Aquadex's role in critical care. The findings emphasize precision ultrafiltration as a complement to traditional therapies, enhancing patient stability and recovery.

    StockTitan·
    US
    NUWE
    -1.14%
    StockTitan·
    US
    NUWE
    -1.14%

    Nuwellis (NUWE) Gets a Hold from Maxim Group

    Maxim Group analyst Anthony Vendetti maintained a Hold rating on Nuwellis, with shares closing at $2.27. Vendetti, who covers the Healthcare sector, has an average return of -25.0% and a 24.60% success rate. The consensus among analysts is a Hold rating for Nuwellis.

    Tip Ranks·
    US
    NUWE
    -1.14%
    Tip Ranks·
    US
    NUWE
    -1.14%

    Nuwellis | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 2.217 M

    LB filings·
    US
    NUWE
    -1.14%
    LB filings·
    US
    NUWE
    -1.14%

    Nuwellis | 8-K: FY2025 Q3 Revenue Misses Estimate at USD 2.217 M

    LB filings·
    US
    NUWE
    -1.14%
    LB filings·
    US
    NUWE
    -1.14%

    Medical tech firm Nuwellis Q3 revenue down 6% yr/yr

    Nuwellis reported a 6% year-over-year decline in Q3 revenue, totaling $2.22 million, but saw a 29% increase sequentially. The company achieved a net income of $468,000, with earnings per share of $0.56. Nuwellis is transitioning its manufacturing to focus on U.S. market growth and is exiting international operations. The firm is enhancing its product offerings and advancing pediatric product development through a collaboration funded by the NIH.

    Reuters·
    US
    NUWE
    -1.14%
    Reuters·
    US
    NUWE
    -1.14%
    © 2026 Longbridge｜Disclaimer